• English
  • Korean
  • Chinese
表紙
市場調査レポート - 224399

バイオテクノロジー市場調査レビュー

2013 Biotechnology Research Review

発行 BCC Research
出版日 ページ情報 英文 96 Pages
価格
バイオテクノロジー市場調査レビュー 2013 Biotechnology Research Review
出版日: 2013年12月05日 ページ情報: 英文 96 Pages
概要

世界のRNAi市場は、2012年に2億1020万米ドルとなりました。同市場は、2013年には2億2030万米ドル、その後5.7%のCAGRで拡大を遂げ、2018年には2億9000万米ドルに達することが予測されています。2012年に2億3170万米ドルとなった次世代シークエンシング市場は、2013年には5億1070万米ドル、2018年には76億米ドルとなる見通しです。また、バイオインフォマティクス市場における実績は2011年が28億米ドル、2012年はおよそ32億米ドルでした。今後の予測では、2017年には75億米ドルに達する見込みです。

当レポートでは、今後大幅な発展が見込まれるバイオテクノロジー産業に注目し、BCC Researchが2013年レポートで取り上げたRNAi技術、次世代シークエンシング、バイオインフォマティクス、 メタボロミクス、 RNAiドラッグデリバリー、およびタンパク質薬物の分野における科学研究・応用開発および市場の動向を見直しながら、バイオテクノロジー産業全体の世界的概況と各分野の将来性をより明確に把握するための数値データをまとめ、概略以下の構成でお届けします。

第1章 バイオテクノロジー市場調査レビュー - はじめに

  • 序文

第2章 RNAi技術と世界市場 (BIO127A)

  • イントロダクション
  • サマリー
  • RNAi技術の概要
  • RNAiの発見
  • RNAi遺伝子のサイレンシングの手法
  • マイクロRNA
  • RNAiの用途
    • RNAiの研究ツールと試薬
    • RNAi薬剤の開発
    • RNAi診断法:マイクロRNAの診断法
    • 農業でのRNAiの活用
  • RNAi市場の概要
  • 知的所有権
  • RNAi市場の将来性

第3章 次世代シークエンシング:新たな臨床用途と世界市場 (BIO126A)

  • イントロダクション
  • エグゼクティブ・サマリー
  • 概要
  • 臨床向け次世代シークエンシング市場
  • 臨床向け次世代シークエンシング市場の成長促進要因
  • 臨床向け次世代シークエンシングの用途
  • 臨床向け次世代シークエンシング産業

第4章 バイオインフォマティクス:技術と世界市場 (BIO051B)

  • イントロダクション
  • サマリー
  • バイオインフォマティクスの概略
  • 創薬におけるバイオインフォマティクス
  • 市場促進要因
  • 市場抑制要因
  • 現在の市場
  • 地域別の市場
  • カテゴリー別の市場
  • 用途別の市場

第5章 メタボロミクス:技術と世界市場 (BIO055A)

  • イントロダクション
  • サマリー
  • 概要
  • メタボロミクス研究の戦略
  • メタボロミクス研究の技術と分析的アプローチ

第6章 タンパク質医薬品の世界市場と製造技術 (BIO021D)

  • イントロダクション
  • サマリー
  • 定義
  • 歴史
  • 治療用タンパク質の薬理的分類
  • 製造技術
  • 治療用タンパク質の分子的な分類
    • サイトカイン
    • 抗体
    • 血液製剤
    • ペプチド系抗生物質
    • ワクチン
    • 酵素
    • ペプチドホルモン

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

The global RNAi research tool and reagent, therapeutic, diagnostic, and agriculture market was valued at $210.2 million in 2012. The RNAi market is expected to reach $220.3 million in 2013 and $290 million by 2018, with a compound annual growth rate (CAGR) of 5.7% for the period of 2013 to 2018.

The next generation sequencing market reached $231.7 million in 2012. The market is expected to reach $510.7 million in 2013 and $7.6 billion in 2018 for a CAGR of 71.6%.

The global bioinformatics market was valued at nearly $2.8 billion in 2011, nearly $3.2 billion in 2012, and is forecast to grow to nearly $7.5 billion by 2017 after increasing at a CAGR of 18.7%.

REPORT SCOPE

FOREWORD

Research Reviews from BCC Research provide market professionals with concise market coverage within a specific research category. These Research Reviews include portions of several market research reports that were published in 2013, and are an efficient way for market professionals to keep up with the general market developments of 2013.

Please note that page references in the text are to pages in the original, complete report, and do not reflect the actual page numbers in this Research Review.

This 2013 Biotechnology Research Review includes excerpts from the following reports:

  • BIO127A RNAi Technologies and Global Markets.
  • BIO126A Next Generation Sequencing: Emerging Clinical Applications and Global Markets.
  • BIO051B Bioinformatics: Technologies and Global Markets.
  • BIO055A Metabolomics: Technologies and Global Markets.
  • BIO021D Global Markets and Manufacturing Technologies for Protein Drugs.

We encourage you to obtain and benefit from the full market research reports that are excerpted in this Research Review.

BCC Research looks forward to serving your market intelligence needs in the future.

Table of Contents

CHAPTER 1 2013 BIOTECHNOLOGY RESEARCH REVIEW 2

  • FOREWORD 2

CHAPTER 2 RNAI TECHNOLOGIES AND GLOBAL MARKETS (REPORT BIO127A) 4

  • INTRODUCTION 4
    • STUDY GOALS AND OBJECTIVES 4
    • REASONS FOR DOING THE STUDY 4
    • SCOPE OF REPORT 5
    • METHODOLOGY AND INFORMATION SOURCES 5
    • INTENDED AUDIENCE 5
    • ANALYST CREDENTIALS 5
    • RELATED REPORTS 5
  • SUMMARY 6
  • TABLE 1 GLOBAL RNAI RESEARCH TOOL AND REAGENT, THERAPEUTIC, DIAGNOSTIC AND AGRICULTURE MARKET, THROUGH 2018 ($ MILLIONS) 7
  • FIGURE 1 GLOBAL RNAI RESEARCH TOOL AND REAGENT, THERAPEUTIC, DIAGNOSTIC AND AGRICULTURE MARKET, 2011-2018 ($ MILLIONS) 7
  • OVERVIEW OF RNAI TECHNOLOGIES 7
  • RNAI DISCOVERY 9
  • RNAI GENE-SILENCING MECHANISM 9
  • FIGURE 2 SIMPLIFIED SCHEMATIC REPRESENTATION OF THE RNAI MECHANISM 9
  • MICRORNA 10
  • TABLE 2 MICRORNA DATABASES 11
  • TABLE 3 COMPUTATIONAL TOOLS FOR MIRNA TARGET PREDICTION 12
  • RNAI APPLICATIONS 12
    • RNAI RESEARCH TOOLS AND REAGENTS 12
    • RNAI DRUG DEVELOPMENT 12
      • RNAi Drug Delivery 13
        • Stability 13
        • Size Limitation 13
        • Cellular Uptake 14
        • Immune Response Activation 14
        • Targeting 14
      • RNAi Drug Design 14
    • RNAI DIAGNOSTICS: MICRORNA DIAGNOSTICS 15
    • RNAI IN AGRICULTURE 15
  • RNAI MARKET OVERVIEW 15
  • TABLE 4 GLOBAL PHARMACEUTICAL MARKET, MARKET SHARES BY REGION AND TOP COMPANIES (%/$ MILLIONS/$ BILLIONS) 16
    • RNAI AS A POSSIBLE TECHNOLOGICAL PREMATURITY 17
    • MERCK AND RNAI 17
      • Acquisition of Sirna Therapeutics 17
      • RNAi Research Center Closure 18
      • Merck's Continued Interest in RNAi 18
    • ROCHE AND RNAI 18
      • Alliance with Alnylam 18
      • Alliance Termination 19
      • Transfers RNAi Assets to Arrowhead Research 19
    • PFIZER AND RNAI 19
    • NOVARTIS AND RNAI 19
    • ABBOTT AND RNAI 20
    • ALNYLAM AND RNAI 20
      • Alnylam and Tekmira 20
      • Kyowa Hakko, Ascletis and Sanofi Alliances 20
      • Future of Alnylam 21
    • TEKMIRA'S PARTNERS 21
    • DICERNA PHARMACEUTICALS FINANCING 22
    • REGULUS INITIAL PUBLIC OFFERING 22
    • MARINA-DEBIOPHARM PARTNERSHIP 22
  • INTELLECTUAL PROPERTY IN THE RNAI MARKETPLACE 22
  • TABLE 5 COMPARISON OF U.S. AND EUROPEAN PATENT SYSTEMS 23
    • U.S. SUPREME COURT: HUMAN GENES CANNOT BE PATENTED 23
    • PATENT ANALYSIS 25
    • TABLE 6 PATENT AND PATENT APPLICATION SEARCHES IN RNAI MARKETPLACE USING VARIOUS KEYWORDS, AS OF AUG. 2013 25
    • TABLE 7 PATENTS AND PATENT APPLICATIONS FOR RNAI DRUG COMPANIES, AS OF AUG. 2013 26
  • RNAI MARKETPLACE FUTURE 26

CHAPTER 3 NEXT GENERATION SEQUENCING: EMERGING CLINICAL APPLICATIONS AND GLOBAL MARKETS (REPORT BIO126A) 29

  • INTRODUCTION 29
    • STUDY GOALS AND OBJECTIVES 29
    • REASONS FOR DOING THE STUDY 29
    • CONTRIBUTION OF THE STUDY AND INTENDED AUDIENCE 30
    • SCOPE AND FORMAT 30
    • METHODOLOGY 31
    • INFORMATION SOURCES 31
    • RELATED BCC REPORTS 31
    • ANALYST CREDENTIALS 32
  • EXECUTIVE SUMMARY 32
  • TABLE 8 CLINICAL NEXT GENERATION SEQUENCING MARKET BY DISEASE CLASS, THROUGH 2018 ($ MILLIONS) 33
  • FIGURE 3 CLINICAL NEXT GENERATION SEQUENCING MARKET BY DISEASE CLASS, 2012-2018 ($ MILLIONS) 33
  • OVERVIEW 34
  • TABLE 9 REPORT SCOPE 35
  • CLINICAL NEXT GENERATION SEQUENCING MARKET 35
  • TABLE 10 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY DISEASE, THROUGH 2018 ($ MILLIONS) 36
  • DRIVING FORCES OF THE GROWTH OF CLINICAL NEXT GENERATION SEQUENCING 37
    • TECHNOLOGY DRIVERS 37
    • TABLE 11 KEY TECHNOLOGY DRIVERS FOR CLINICAL NEXT GENERATION SEQUENCING 37
    • MARKET DRIVERS 38
    • TABLE 12 CLINICAL NEXT GENERATION SEQUENCING MARKET DRIVING FORCES 39
  • CLINICAL NEXT GENERATION SEQUENCING APPLICATIONS 40
  • TABLE 13 CLINICAL NEXT GENERATION SEQUENCING APPLICATION STATUS 40
  • CLINICAL NEXT GENERATION SEQUENCING INDUSTRY 41
  • TABLE 14 KEY DIAGNOSTIC NEXT GENERATION SEQUENCING INDUSTRY PARTICIPANTS BY SECTOR 41

CHAPTER 4 BIOINFORMATICS: TECHNOLOGIES AND GLOBAL MARKETS (REPORT BIO051B) 44

  • INTRODUCTION 44
    • STUDY GOALS AND OBJECTIVES 44
    • REASONS FOR DOING THE STUDY 44
    • SCOPE OF REPORT 44
    • INTENDED AUDIENCE 45
    • METHODOLOGY AND INFORMATION SOURCES 45
    • ANALYST CREDENTIALS 46
    • RELATED BCC REPORTS 46
  • SUMMARY 46
  • TABLE 15 BIOINFORMATICS MARKET BY REGION, THROUGH 2017 ($ MILLIONS) 47
  • FIGURE 4 BIOINFORMATICS MARKET BY REGION, 2011-2017 ($ MILLIONS) 47
  • INTRODUCTION TO BIOINFORMATICS 49
  • FIGURE 5 BIOINFORMATIC RELATIONSHIP TO 'OMIC TECHNOLOGIES 50
    • BIOLOGICAL DATA SOURCES 50
    • BIOINFORMATICS IN TRANSLATIONAL MEDICINE: A SYSTEM BIOLOGY APPROACH 51
    • FIGURE 6 SYSTEMS BIOLOGY PRINCIPAL APPROACHES 52
  • BIOINFORMATICS IN DRUG DEVELOPMENT 53
  • MARKET DRIVERS 54
  • MARKET RESISTORS 55
  • CURRENT MARKET 56
  • MARKET BY REGION 56
  • TABLE 16 BIOINFORMATICS MARKET BY REGION, THROUGH 2017 ($ MILLIONS) 56
  • MARKET BY CATEGORY 57
  • TABLE 17 BIOINFORMATICS MARKET BY CATEGORY, THROUGH 2017 ($ MILLIONS) 57
  • MARKET BY APPLICATION 58
  • TABLE 18 BIOINFORMATICS MARKET BY APPLICATION, THROUGH 2017 ($ MILLIONS) 59

CHAPTER 5 METABOLOMICS: TECHNOLOGIES AND GLOBAL MARKETS (REPORT BIO055A) 61

  • INTRODUCTION 61
    • STUDY GOALS AND OBJECTIVES 61
    • REASONS FOR DOING THIS STUDY 61
    • SCOPE AND FORMAT 62
    • METHODOLOGY AND INFORMATION SOURCES 62
    • INTENDED AUDIENCE 62
    • ANALYST CREDENTIALS 62
    • RELATED REPORTS 63
  • SUMMARY 63
  • TABLE 19 GLOBAL MARKET FOR METABOLOMICS TECHNOLOGIES AND APPLICATIONS, THROUGH 2017 ($ MILLIONS) 65
  • FIGURE 7 GLOBAL MARKET FOR METABOLOMICS TECHNOLOGIES AND APPLICATIONS, 2010-2017 ($ MILLIONS) 65
  • OVERVIEW 65
  • TABLE 20 NUMBER OF PUBLICATIONS FROM 2000-2012 USING THE KEYWORD "METABOLOMICS" IN THE SEARCH 68
  • FIGURE 8 NUMBER OF PUBLICATIONS FROM 2000-2012 USING THE KEYWORD "METABOLOMICS" IN THE SEARCH 69
  • STRATEGIES IN METABOLOMICS RESEARCH 69
  • TABLE 21 MAIN APPROACHES IN METABOLOMICS RESEARCH 70
    • TARGETED ANALYSIS 70
    • METABOLIC FINGERPRINTING 70
    • METABOLITE PROFILING 71
  • TECHNOLOGIES AND ANALYTICAL APPROACHES IN METABOLOMICS RESEARCH 71
  • FIGURE 9 SCHEMATIC REPRESENTATION OF EXPERIMENTAL METABOLOMIC APPROACHES 72
    • IMPORTANCE OF BIOINFORMATICS RESOURCES FOR METABOLOMICS RESEARCH 72
    • APPLICATIONS OF METABOLOMICS RESEARCH 73

CHAPTER 6 GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS (REPORT BIO021D) 77

  • INTRODUCTION 77
    • STUDY OBJECTIVES 77
    • REASONS FOR DOING THIS STUDY 77
    • INTENDED AUDIENCE 77
    • SCOPE OF THE STUDY 78
    • METHODOLOGY 78
    • INFORMATION SOURCES 78
    • ABOUT THE AUTHOR 78
    • RELATED BCC RESEARCH REPORTS 79
  • SUMMARY 79
  • TABLE 22 GLOBAL REVENUE OF PROTEIN THERAPEUTICS MARKET, THROUGH 2018 ($ MILLIONS) 80
  • FIGURE 10 GLOBAL REVENUE OF PROTEIN THERAPEUTICS MARKET, 2011-2018 ($ MILLIONS) 80
  • DEFINITIONS 81
  • HISTORY 81
  • TABLE 23 EVOLUTION OF THERAPEUTIC PROTEINS 82
  • PHARMACOLOGICAL CLASSIFICATION OF THERAPEUTIC PROTEINS 83
    • PROTEIN THERAPEUTICS WITH ENZYMATIC OR REGULATORY ACTIVITY 83
    • PROTEIN THERAPEUTICS WITH SPECIAL TARGETED ACTIVITY 84
    • PROTEIN VACCINES 84
  • MANUFACTURING TECHNOLOGIES 84
    • NATURAL SOURCING AND EXTRACTION 85
    • TABLE 24 PROTEIN DRUGS MADE BY HUMAN SOURCE EXTRACTION 86
    • TABLE 25 PROTEIN DRUGS MADE BY ANIMAL SOURCE EXTRACTION 86
    • MICROBIAL FERMENTATION 87
    • TABLE 26 PROTEIN DRUGS MADE BY MICROBIAL FERMENTATION 88
    • TRANSGENICS 88
    • TABLE 27 PROTEIN DRUGS MADE BY TRANSGENIC ORGANISMS 89
    • MAMMALIAN CELL CULTURE 89
    • TABLE 28 PROTEIN DRUGS MADE BY MAMMALIAN CELL CULTURE 90
    • OTHER CELL CULTURE SYSTEMS 90
    • TABLE 29 PROTEIN DRUGS MADE BY INSECT CELL CULTURE 90
  • MOLECULAR CLASSIFICATION OF THERAPEUTIC PROTEINS 90
    • CYTOKINES 91
      • Colony-Stimulating Factors 91
      • Interferons 91
      • Interleukins 92
    • ANTIBODIES 92
    • BLOOD PRODUCTS 93
      • Alpha-1-Proteinase Inhibitor 93
      • Antihemophilic Factor 93
      • Antithrombin 94
      • C1 Esterase Inhibitor 94
      • Coagulation Factors 95
      • Immunoglobulins 95
      • Protein C 96
      • Thrombin 96
    • PEPTIDE ANTIBIOTICS 96
    • VACCINES 97
    • ENZYMES 98
      • Digestive Enzymes 98
      • Lysosomal Enzymes 99
      • Thrombolytic Enzymes 99
      • Other Enzymes 100
    • PEPTIDE HORMONES 100
      • Follicle-Stimulating Hormone and Luteinizing Hormone 101
      • Adrenocorticotropic Hormone 101
      • Growth Hormones 101
      • Erythropoietin 101
      • Insulin 102

LIST OF TABLES

  • TABLE 1 GLOBAL RNAI RESEARCH TOOL AND REAGENT, THERAPEUTIC, DIAGNOSTIC AND AGRICULTURE MARKET, THROUGH 2018 ($ MILLIONS) 7
  • TABLE 2 MICRORNA DATABASES 11
  • TABLE 3 COMPUTATIONAL TOOLS FOR MIRNA TARGET PREDICTION 12
  • TABLE 4 GLOBAL PHARMACEUTICAL MARKET, MARKET SHARES BY REGION AND TOP COMPANIES (%/$ MILLIONS/$ BILLIONS) 16
  • TABLE 5 COMPARISON OF U.S. AND EUROPEAN PATENT SYSTEMS 23
  • TABLE 6 PATENT AND PATENT APPLICATION SEARCHES IN RNAI MARKETPLACE USING VARIOUS KEYWORDS, AS OF AUG. 2013 25
  • TABLE 7 PATENTS AND PATENT APPLICATIONS FOR RNAI DRUG COMPANIES, AS OF AUG. 2013 26
  • TABLE 8 CLINICAL NEXT GENERATION SEQUENCING MARKET BY DISEASE CLASS, THROUGH 2018 ($ MILLIONS) 33
  • TABLE 9 REPORT SCOPE 35
  • TABLE 10 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY DISEASE, THROUGH 2018 ($ MILLIONS) 36
  • TABLE 11 KEY TECHNOLOGY DRIVERS FOR CLINICAL NEXT GENERATION SEQUENCING 37
  • TABLE 12 CLINICAL NEXT GENERATION SEQUENCING MARKET DRIVING FORCES 39
  • TABLE 13 CLINICAL NEXT GENERATION SEQUENCING APPLICATION STATUS 40
  • TABLE 14 KEY DIAGNOSTIC NEXT GENERATION SEQUENCING INDUSTRY PARTICIPANTS BY SECTOR 41
  • TABLE 15 BIOINFORMATICS MARKET BY REGION, THROUGH 2017 ($ MILLIONS) 47
  • TABLE 16 BIOINFORMATICS MARKET BY REGION, THROUGH 2017 ($ MILLIONS) 56
  • TABLE 17 BIOINFORMATICS MARKET BY CATEGORY, THROUGH 2017 ($ MILLIONS) 57
  • TABLE 18 BIOINFORMATICS MARKET BY APPLICATION, THROUGH 2017 ($ MILLIONS) 59
  • TABLE 19 GLOBAL MARKET FOR METABOLOMICS TECHNOLOGIES AND APPLICATIONS, THROUGH 2017 ($ MILLIONS) 65
  • TABLE 20 NUMBER OF PUBLICATIONS FROM 2000-2012 USING THE KEYWORD "METABOLOMICS" IN THE SEARCH 68
  • TABLE 21 MAIN APPROACHES IN METABOLOMICS RESEARCH 70
  • TABLE 22 GLOBAL REVENUE OF PROTEIN THERAPEUTICS MARKET, THROUGH 2018 ($ MILLIONS) 80
  • TABLE 23 EVOLUTION OF THERAPEUTIC PROTEINS 82
  • TABLE 24 PROTEIN DRUGS MADE BY HUMAN SOURCE EXTRACTION 86
  • TABLE 25 PROTEIN DRUGS MADE BY ANIMAL SOURCE EXTRACTION 86
  • TABLE 26 PROTEIN DRUGS MADE BY MICROBIAL FERMENTATION 88
  • TABLE 27 PROTEIN DRUGS MADE BY TRANSGENIC ORGANISMS 89
  • TABLE 28 PROTEIN DRUGS MADE BY MAMMALIAN CELL CULTURE 90
  • TABLE 29 PROTEIN DRUGS MADE BY INSECT CELL CULTURE 90

LIST OF FIGURES

  • FIGURE 1 GLOBAL RNAI RESEARCH TOOL AND REAGENT, THERAPEUTIC,
  • DIAGNOSTIC AND AGRICULTURE MARKET, 2011-2018 ($ MILLIONS) 7
  • FIGURE 2 SIMPLIFIED SCHEMATIC REPRESENTATION OF THE RNAI MECHANISM 9
  • FIGURE 3 CLINICAL NEXT GENERATION SEQUENCING MARKET BY DISEASE CLASS, 2012-2018 ($ MILLIONS) 33
  • FIGURE 4 BIOINFORMATICS MARKET BY REGION, 2011-2017 ($ MILLIONS) 47
  • FIGURE 5 BIOINFORMATIC RELATIONSHIP TO 'OMIC TECHNOLOGIES 50
  • FIGURE 6 SYSTEMS BIOLOGY PRINCIPAL APPROACHES 52
  • FIGURE 7 GLOBAL MARKET FOR METABOLOMICS TECHNOLOGIES AND APPLICATIONS, 2010-2017 ($ MILLIONS) 65
  • FIGURE 8 NUMBER OF PUBLICATIONS FROM 2000-2012 USING THE KEYWORD "METABOLOMICS" IN THE SEARCH 69
  • FIGURE 9 SCHEMATIC REPRESENTATION OF EXPERIMENTAL METABOLOMIC APPROACHES 72
  • FIGURE 10 GLOBAL REVENUE OF PROTEIN THERAPEUTICS MARKET, 2011-2018 ($ MILLIONS) 80
Back to Top